

Index

- ADJUST option, 413, 427
agriculture, 26
Akaike's information criterion, 224, 405
 PROC MIXED, 405
amantadine, 287–289
analgesic trial, 285–287
analysis of covariance, 15, 17
animal breeding, 26
animal disease, cluster sample, 365–366
animal feeding, 73–74
animal physiology trial (breathing),
 355–361
ANOVA, 5, 8, 9, 25
 repeated measures, 217
anti-anxiety agent, 383
apoptosis, 375, 376
approximation, and bias, 133
area under curve (AUC), 216, 317
asthma, 311, 372, 393
ASYCOV option, 406
autoregression: *see* first-order autoregressive
 correlation
average bioequivalence, 378, 382

Balaam's design, 287–289
balance, 27–30
 continuous effect, 30
 least squares, 49
 multi-centre, 197
 unbalanced design, 309
banded covariance, 223
base density, 68
baseline covariate, 137
 cross-over, 276
 fixed effects, 276

hypertension study, 13–16
linearity assumption, 13–16
pre-treatment, 247
Bayesian approach
 classical statistics comparison, 56
 'cold feet' analysis, 141
 empirical Bayes, 66–67
 exact statistics, 58
 GLMM significance testing, 135–136
 historical, 26
 hypertension trial analysis, 83–85
 negative variance components, 73
 parameter estimation, 60
 pre-eclampsia, 205, 206
 software (BUGS), 403
 software (PROC MIXED), 420–421
 standard error bias, 75
 see also posterior density; posterior
 distribution; prior distribution
Bernoulli distribution, 109
 general exponential form, 117
 variance matrix, 114
Bernoulli form, 128, 428
 dispersion parameter, 134
 GLIMMIX, 204
 pre-eclampsia, 204–213
beta distribution, 65
between-subject design
 animal physiology, 357
 different variances, 351–354
bias
 of approximations, 133
 Bayesian models, 59
 cross-over, 309
 dispersion parameter, 133–135

- bias (*continued*)
 empirical estimator, 227
 fixed effects, 49
 GLMM, 133
 mixed model, 25
 ML estimates, 47
 pseudo-likelihood, 126, 127
 random effects, 128, 132
 random effects prediction, 52
 shrinkage, 131–132, 134, 161–162
see also error; standard error
- binary data
 cross-over, 299–303
 dispersion parameter, 114
 extended binary form, 155, 163
 matched sets, 339
 modelling, 109–111
 odds ratio, 301, 309
 sample size estimation, 201, 270
see also Bernoulli form; binomial form;
 parameterisation
- binomial distribution, 110, 114
 exponential form, 118
 variance matrix, 114
- binomial form, 128, 428
 covariance pattern model, 424
 dispersion parameter, 133
 mortality estimate, 370
- bioavailability, 378
- bioequivalence, 311, 378
- bioequivalence trials, 311
- bivariate normal distribution, 21
- block diagonal matrix, 40, 43
- blocking effect, 30, 218, 428
 covariance pattern, 30, 43–44
 error stratum, 31
G matrix, 45, 261, 412
R matrix, 43
 random coefficients model, 30
 REPEATED statement, 354
- blood pressure: *see* hypertension
- Breast screening, 395–396
 Edinburgh randomised trial of, 395–396
- breathing trial: *see* animal physiology trial
- BUGS, 403
 Gibbs sampling, 70
- cancer
 children's (herpes virus study), 252–267
 ovarian, 246
- canonical link function: *see under* link
 function
- cardiac output trial
 complete block design, 279–280
 covariance pattern model, 291–296
- cardiology: *see* heart failure; hypertension
- cardiology trial, dogs, 363–365
- carry-over
 Balaam's design, 287–289
 critiqued, 287
 four-period, four-treatment, 279–280
 information recovery, 286
 Koch's design, 284–285, 291
 model choice, 295
 standard error, 288
- case control studies: *see* matched
 case-control studies
- categorical data
 cross-over trial, 303–305
 sample size, 202, 270
 unordered, 166
see also mixed ordinal logistic regression;
 ordinal logistic regression;
 unordered categorical data
- categorical effects, 35
X matrix, 35
- categorical mixed model, 153–181
 'cold feet' analysis, 169, 181
 epilepsy trial, 242
 GLMM comparison, 224
 model checking, 168, 342–343
- CD4 count, 250–252
- centre effects
 model analysis, 184–188
 model checking, 91
 random, 352–354
see also centre-treatment effects
- centre-treatment effects, 185–187
 binary data, 184–188
 'cold feet' analysis, 144
 DBP analysis, 89, 93
 different variances, 352–354
 model analysis, 184–188
 negative variance components, 196
 random effects model, 16
see also multi-centre trial; treatment effect
 estimates
- centre-treatment interaction
 normal mixed models, 85–87
 plausibility, 195
- centres

- number of, 196
- size, 196
- cerebrovascular insufficiency, 299–303
- change score, 300, 304
 - contingency table, 305
- chemotherapy: *see* herpes virus cancer study
- chi-squared test, 78, 209
 - CHISQ option, 418, 425
 - GLM, 135
 - Pearson, 209
 - test for trend (contingency table), 109, 153
 - Wald statistic, 205, 427
- childhood cancer study, 252–267
- CL option, 406, 408, 410, 414
- cluster randomised trials, 392–396
 - asthma treatment, 392–393
- 'cold feet' analysis: *see under* hypertension study
- cluster sample survey, 365–366
- communicating results, 24, 57
- complete block designs, 279–280
- compound symmetry pattern, 44
- conditional distribution, 69
- conditional logistic regression, 119
- confidence intervals
 - 'cold feet' analysis, 144
 - ESTIMATE statement, 414
 - GLM(M), 136
 - LSMEANS statement, 413
 - MODEL statement, 406, 407
 - normal mixed model, 79
- conjugacy, 65
- containment, 27–28
 - ESTIMATE statement, 414–417
- containment stratum, 30–32
- contingency table analysis
 - dysmenorrhoea trial, 303–305
 - GLM superiority, 109
 - logistic regression, 153
- contrast, 76–78, 427
- CONTRAST statement, 417–418
- convergence
 - Bayesian methods, 58
 - GEE, 124
 - Gibbs sampling, 67, 68
 - GLM, 117
 - GLMM, 129
 - iterative methods, 53–54
 - Newton–Raphson, 53
 - PROC MIXED, 254, 405
 - pseudo-likelihood, 126
 - shrinkage, 161
 - uniform effect categories, 129–130, 134
- CORR option, 410, 429
- correlation
 - compound symmetry, 44
 - negative, 73–74
 - sample size, 267–270
- cot death study, 339–351
 - binary variables, 343
- count data, 110, 237
 - categorical mixed model, 243
 - GLMM, 243
 - sample size, repeated measures, 270
 - see also under* covariance pattern model:
 - Poisson distribution
- covariance matrix: *see* V matrix
- covariance parameters
 - categorical mixed model, 242
 - exponential decay, 229
 - fixed/mixed comparison, 19–20
 - nested, 224: *see also* nesting
- R** matrix, 168
 - simple model, 19–20
- covariance pattern
 - compound symmetry model, 220–221
 - count data, 237–245
 - first-order autoregressive, 219–221, 225
 - general (unstructured), 219
 - heterogeneous, 221
 - SAS, 418, 425
 - simple, 219–221
 - Toeplitz, 220, 231
- covariance pattern choice
 - categorical mixed models, 168
 - repeated measures, 223–225, 316
 - strategy for, 225, 316
 - and trial size, 231
- covariance pattern model, 19–21, 160–162, 343
 - blocking variable, 30, 218–219
 - compound symmetry structure, 295
 - cross-over trial, 135, 272, 290–296
 - dispersion parameter, 135
 - error stratum, 31
 - first-order autoregressive, 315
 - four-way cross-over trial, 291–296
 - GLMM V matrix, 121
 - historical, 26
 - mixed ordinal logistic regression, 160
 - model fitting, 229–231

- covariance pattern model, (*continued*)
 - multi-centre trial with repeated measures, 332–334
 - normal data, 228–237
 - model checking, 231–238
 - pattern selection, 229–231
 - number of parameters, 167
 - quasi-likelihood, 123
 - random coefficients model comparison, 325
 - from reparameterisation, 127
 - repeated measures, 218–228
 - REPEATED statement, 418–419
 - repeated within visits, 312–317
 - see also* reparameterisation
- covariance structure
 - covariance pattern models, 43–45
 - likelihood ratio test, 317
 - random coefficients model, 41–43
 - random effects model, 38–40
 - SAS options, 412
- covariate effects
 - parameters, 35
 - X** matrix, 35
- Crohn's disease, 375
- cross-over trial
 - AB/BA, 272–278, 299–303
 - Balaam's design, 287–289
 - balance, 29
 - binary data analysis, 299–303
 - categorical data, 303–305
 - complete block, 279–280
 - covariance pattern models, 135, 272, 290–296
 - defined, 271
 - error stratum, 30–32
 - fixed effects model, 34
 - four-way, 291–296
 - higher order complete block designs, 279–280
 - incomplete block designs, 284–287
 - Koch's design, 284–285
 - matched studies similarity, 339
 - mixed models advantage, 1–3, 23, 272
 - multi-centre, 337
 - non-informative prior, 64, 77
 - optimal designs, 287–289
 - parallel group comparison, 276, 277, 307–308, 356
 - random effects model advantage, 308–310
 - simple model, 3–12
 - structured covariance pattern model, 290–296
 - by time, 290
 - by treatment, 290
 - trial design, 307–308
 - two-period, 285–287
- cubic random coefficients model, 254, 260
- cumulative probability, 154, 155
- data transformation, 80
- DDFM option, 406, 407
- degrees of freedom (DF)
 - confidence intervals, 79
 - F* tests, 77–78
 - negative variance, 71, 196
 - REML adjustment, 25
 - SAS default, 407
 - variance parameter accuracy, 48, 49, 76, 142
 - see also* Satterthwaite DF
- density function, 117, 118
 - canonical link function, 112
 - general exponential form, 111
 - likelihood function, 45
- deprivation score, 340–342
- design matrix: *see* **X** matrix; **Z** matrix
- DIFF option, 413, 427
- dispersion parameter, 114–115
 - and bias, 133
 - 'cold feet' analysis, 143
 - covariance pattern model, 135
 - fitting, 133–135
 - GLIMMIX macro, 423
 - GLM, 133–134
 - GLMM, 121, 134–135
- diuretic treatment
 - heart failure, 275, 276
 - pre-eclampsia, 204–213
- dose response studies: *see* repeated measures within visits
- dropout, 1–3, 91
 - cot death study, 345
 - DBP analysis, 94
 - hypertension trial, 12
 - repeated measures, 3, 226
- drug registration, 295
- dysmenorrhoea, 303–305

- E option, 414
 E3 option, 408, 409
 eczema treatment, 372–374
 efficiency, 274
 Egret, 401
 electrocardiogram assessment, 299–303
 empirical Bayes, 66–67
 EMPIRICAL option, 76, 228, 407
 empirical variance, 76, 133, 227
 PROC GENMOD, 300, 425
 epilepsy trial, 108, 237, 242
 categorical mixed model, 242
 GLMM analysis, 243
 sample size, 270
 error
 model choice, 6, 295
 residual variance, 71
 sample size, 309
 variance parameters, 74
 see also bias; residual; standard error
 error stratum, 30
 higher level, 31
 mixed models information recovery, 31
 multi-centre trial, 184
 hypertension trial, REML, 84
 ESTIMATE statement, 190, 327, 414–417
 non-estimable, 415
 non-estimable effects, 415
 ethics
 medical studies, 25
 sample size calculation, 267
 trial design, 356
 event history analysis, 372–374
 exact logistic regression, 134
 experiment design, sample size, 356–361
 explaining results, 24, 58
 exponential family, 107, 111–112
 see also GLM
 exponential form, general, 111–112,
 117–119
 extended binary form, 163

 F distribution, 71
 F test, 5
 CONTRAST statement, 417
 contrasts, 77
 denominator DF, 77–78
 GLM(M), 135
 PROC MIXED, 406
 repeated measures, 226

 factor effects: *see* categorical effects
 farm, disease prevalence, 365
 FDA, 378, 381
 first-order autoregressive correlation,
 219–221
 Fisher scoring, 54
 fixed effects estimates, 49–50
 categorical mixed model, 243
 covariance pattern models, 22
 fixed effects matrix: *see* X matrix
 fixed effects model, 34–36
 assessing fixed effects, 231
 assumptions, 6
 balance, 28
 cerebrovascular insufficiency, 299–303
 complete block designs, 279–280
 GEE, 124
 incomplete data, 7, 272
 matched sets, 339
 mixed models comparison, 7
 multi-centre trial, 184–185, 188–190
 outliers, multi-centre trial, 184
 random coefficients comparison, 246
 random effects model, 7
 repeated measures, 216–217
 choice, 225–226
 significance testing, 76–79
 uniform categories, 129–130, 134
 see also contingency table analysis; GLM
 foetal scans, 361–362
 Fortran software, model fitting, 163
 4 × 4 factorial design
 laboratory study of, 375–378

G matrix
 covariance pattern model, 45
 mixed ordinal logistic regression, 159
 random coefficients model, 42
 random effects model, 38
 SAS, 410, 412
 unordered categorical data, 165–166
 general autoregressive model: *see* Toeplitz
 covariance pattern model
 generalisation of results, 195
 generalised estimating equations (GEEs),
 124–125, 428–430
 generalised least squares: *see* iterative
 generalised least squares
 generalised linear mixed models: *see* GLMM
 generalised linear models: *see* GLM

- generalised logit, 163
 Genstat, 401
 Gibbs sampling, 68–70
 GLIMMIX macro, 125, 149–428
 GLM (generalised linear model),
 107–119
 V matrix, 113–114
 confidence intervals, 136
 contingency table, 108
 defined, 112–115
 dispersion parameter, 133–134
 distributions, 109–111
 fitting, 115–117
 meta-analysis, 204–205
 PROC GENMOD, 146, 428–430
 significance testing, 135
 GLMM (generalised linear mixed model),
 120–128, 428
 categorical model comparison, 224
 confidence intervals, 136
 defined, 120–121
 dispersion parameter, 134–135
 epilepsy trial, 243
 fitting, 124–128
 Bayesian approach, 127
 GEE, 124–125, 428–430
 pseudo-likelihood, 125–127
 likelihood function, 121–122
 meta-analysis, 204–213
 model checking, 136–137
 non-normal data, 201
 quasi-likelihood, 123–124
 sample size, 201
 significance testing, 135–136
 see also GLIMMIX macro; mixed ordinal
 logistic regression; unordered
 categorical data
 global estimates, 184,
 337
 centre and centre-treatment effects
 random, 184
 centre number, 184, 337
 centre-treatment interaction, 184, 337
 cluster sample surveys, 365
 double hierarchical, 338
 effect on standard error, 203
 Goldstein, random effects fitting software, 163
 grid search, 420
 GROUP option, 354, 412
 haemophilia study: *see* HIV
 heart failure (diuretics) study, 275, 276
 Hedeker and Gibbons software, 162–163,
 402
 herpes virus cancer study, 252–267
 antibody level, 252–267
 Hessian matrix, 54, 405
 hierarchical data, 23, 28
 containment, 28
 mixed model, 23
 hierarchical model, 18
 hierarchical structure
 double, 338
 multi-centre trial, 203, 338
 HIV
 linear random coefficients model,
 250–252
 model fitting, 250
 HLM, 402
 hypertension study
 analysis models, 83–85
 baseline covariate, 13–16
 Bayesian model, 146
 between-subject analysis, 352
 categorical ‘cold feet’ analysis, 169
 correlation parameter interpretation,
 171
 odds ratio, 171
 centre effects, 16
 centre-treatment interaction, 16–17
 ‘cold feet’ analysis, 137–141, 152
 data modelling, 13
 fixed effects models, 148
 Hedeker & Gibbons software, 169, 170
 incomplete data, 89–93
 introduction, 12–13
 model checking, 89–93, 152
 models, 137–138
 multi-centre trial, 332–334
 normal data, 228–237
 random effects model, 141
 repeated measures, 18–21, 332–334
 results analysis, 85–87
 sample size, 268
 SAS code, 94–105
 treatment-centre, 199–202
 ID statement, 421
 identity function, as link function, 109, 119
 incomplete block design, 284–287

- incomplete data, 7
 - balance, 30
 - cross-over trial, 272–273
 - DBP analysis, 91
 - mixed model advantage, 1–3, 23
 - not at random, 218
 - randomness requirement, 81
 - repeated measures, 3, 215–218, 311–312
 - unbalanced design, 309
- individual bioequivalence, 381–383
- inference
 - fixed effects model, 188
 - model choice, 184
 - random effects model, 186, 195
 - see also* generalisation of results
- information matrix, 54
- information recovery, 10, 31, 284, 286
 - see also* incomplete data
- integrated care pathways, 392–393
- intention to treat, 83
- inter/intra-observer variability
 - foetal scan, 361–362
 - heart wall thickness, 363–365
- invariance to time origin, 43, 260
- inverse gamma distribution, 61, 65, 142
 - PRIOR statement, 420
- iterative generalised least squares, 48
 - fixed effects estimation, 49
 - incomplete block design, 286
 - random effects prediction, 52
 - restricted, 48, 56
 - variance parameter estimation, 54–56
- iterative methods, 52–54
 - GEE, 126
 - GLM fitting, 115–117
 - Newton–Raphson, 53–54, 115–117
 - pseudo-likelihood maximisation, 125–126
- Jeffreys' method, 64, 421
- Kenward–Roger adjustment, 75–77, 87, 88, 143, 227, 248, 255, 293, 295, 309, 385, 407
- Koch's design, 284–285
- L** matrix, 417, 418
- last value carried forward, 13
- least squares: *see* IGLS; ordinary least squares
- least squares mean, 429
- leukaemia: *see* childhood cancer study
- likelihood function
 - GLM, 115
 - GLMM, 122
 - infinite, 405
 - information criteria measures, 224
 - log likelihood, 45–49
 - GLM fitting, 115
 - GLMM, 122
 - ordinary/REML, 46
 - mixed ordinal logistic regression, 158
 - model fitting, 45–49
 - non-informative prior similarity, 61
 - ordinal logistic regression, 154
 - ordinary/REML, 46
 - standardised, 58
 - true likelihood, 45–49
 - see also* maximum likelihood;
 - pseudo-likelihood; quasi-likelihood;
 - REML
- likelihood ratio test, 224
 - covariance structure determination, 317–318
 - variance components significance, 78, 248
- linear dependencies, **X** matrix, 36
- linearised pseudo variable, 116, 125–126, 137
- link function, 108–109
 - canonical, 109, 112–113, 117, 118
 - GLMM, 120
 - mixed ordinal logistic regression, 154
 - non-canonical, 113
 - see also* log likelihood function; logit link function
- Lipsitz macro
 - parameterisation, 162
 - source, 423
- local estimates, 184, 337
 - centre effects random, 337
 - grid search, 405
 - meta-analysis, 203
- local maximum, PROC MIXED, 405
- location parameter, 60, 111
- log likelihood: *see under* likelihood function
- log link function, 131
- logistic regression, 119
 - conditional, 119
 - see also* conditional logistic regression; logit link function

- logit link function, 117
 Bernoulli, 117
 binomial, 118
 cumulative probability, 154
 generalised, 163
see also link function; log link function
- LSMEANS statement, 413–414
- lung function trial, 355–361
- MAKE statement, 423
- marginal methods, 48
see also REML
- marginal posterior distribution, 59
- Markov chain Monte Carlo methods, 67
 Gibbs sampling, 68–70
- matched case–control studies, 339
 cot death study, 339–351
see also matched sets
- matched sets
 cot death study, 343–345
 fixed effects model, 339
- matrix notation, 33
- matrix, positive semi-definite, 247
- maximum likelihood
 Bayesian comparison, 57
 fixed effects estimation, 49
 historical context, 25
 model fitting, 46
 random effects prediction, 50–52
see also likelihood function; REML
- mean response, 216–217
- median, 60, 85
- meta-analysis, 203–204, 338
 data inclusion criteria, 206
 example, 204–213
 mixed model, 2
- method of scoring: *see* Fisher scoring
- METHOD option, 406
- micturition frequency, 275
- MINQUE option, 406
- missing data: *see* incomplete data
- mixed model, 423
 advantages, 1–3, 23–24
 defined, 2, 22, 36–38
 disadvantages, 24
 historical, 25–26
 incomplete data, 217
 multi-centre trial, 184
see also covariance pattern model; normal mixed model; random coefficients model; random effects model
- mixed ordinal logistic regression
 binary modelling, 154
 covariance pattern model, 160
 defined, 158–159
 as GLMM, 154, 158–163
 model fitting, 162–163, 169, 170
R matrix, 159–161
 software (Hedeker and Gibbons), 162–163, 169, 170, 402
- Mixed-Up suite, 402
- MLwiN, 163, 402
- mode, 60
- model-based approach, covariance pattern models, cross-over trials, 293
- model building, 3–12
 childhood cancer study, 252
 non-linear temporal, 252
 repeated measures, 317
- model checking, 79–80
 categorical mixed, 168
 covariance pattern, 228, 231–237
 DBP analysis
 centre effects, 91, 93
 centre-treatment effects, 93, 93
 GLMM, 136–137
 outliers, 90
 residuals, 89–93
 SAS code, 94
 matched case–control, 342–343
 Pearson residuals, 240
 polynomial random coefficients, 252
 random coefficients, 248, 255
 random effects ‘cold feet’ analysis, 140, 152
see also residual plots
- model choice
 assumptions, 295
 binary data, 309
 covariance pattern model, 295
 multi-centre trial, 184–188
 non-normal data, 309
 small samples, 391
 standard error, 277, 293
- model comparison, covariance pattern models, 224
- model fitting, 45–56
 Bayesian, 56–70
 covariance pattern model

- repeated measures, 224, 229–231
 - systolic blood pressure trial, 317–322
- GLM, 115–117
- GLMM problems, 134–135
- likelihood function, 45–49
- linear random coefficients, 250
- manually, 11
- measures of, 209, 224
- mixed ordinal logistic regression,
 - 162–163, 169, 170
- multi-centre trial with repeated measures,
 - 332–334
- overfitting, 223–224
- parameter estimation, 102–105
- PROC MIXED, 405, 406
- rejection sampling, 67
- statistical comparison, 224
- unordered categorical data, 166
- model selection: *see* model choice
- MODEL statement, 407–410, 428
- Monte Carlo methods, 68–70
- mortality estimates, 367–370
- mouthwash trial, 277, 308
- multi-centre trial
 - analysis considerations, 195–197
 - balance, 197
 - centre effects, 195–197
 - cross-over, 337
 - defined, 183
 - fixed effects model
 - analysis implications, 184–185
 - centre-treatment effects omitted, 187–188
 - outliers, 184
 - hierarchical, 203, 338
 - meta-analysis, 184–188, 203–204
 - data inclusion criteria, 206
 - example, 204–213
 - outliers, 203–204
 - mixed model, 184
 - number of centres, 196
 - random effects model, 204
 - repeated measurements, 330–334
 - sample size estimation, 197–202
- multinomial correlation, **R** matrix,
 - 157–158
- multinomial distribution, mixed ordinal
 - logistic regression, 157
- multinomial probability, unordered
 - categorical, 163
- multiple contrast, 76–78
- multivariate normal distribution
 - checking, 231–237, 249, 255
 - density function, likelihood, 45
 - SAS coding, 261
- negative correlation, 73–74
- nesting, 224–225, 231, 332, 425
- Newton–Raphson iteration, 53–54,
 - 115–117
- nicotine, 375, 376
- NOCLPRINT option, 407
- non-comparative data, 248
- non-estimable effects, 149, 415
- non-normal data
 - distribution, 107, 108
 - likelihood, 123
 - model selection, 309
 - repeated measures, 269–270
 - sample size estimation, 201–202
 - see also* GLM
- NonMem, 402
- normal data
 - covariance pattern model, 228–237
 - sample size estimation, 197–201, 267
- normal distribution
 - assumption checking, 80
 - bivariate, 21
 - link function, 119
 - residual, 4
 - transformation to, 250
 - see also* multivariate normal distribution
- normal mixed model, 33, 36–38
 - Bayesian approach, 56–70
 - fixed effects estimation, 49–50
 - likelihood function, 45–49
 - model fitting, 45–56
 - random effects estimation, 50–52
 - relation to GLM, 107
 - variance parameter estimation,
 - 52–56
 - see also* covariance pattern model; mixed model; random coefficients model; random effects model
- normal probability plots, 80, 89, 137, 152,
 - 342, 343
- null hypothesis, 60, 77
- numerical methods, 52–54, 66

- observer variation
 - binary data, 27, 307, 309
 - categorical data, 248, 303
 - 'cold feet' analysis, 144
 - dog cardiology, 363–364
 - epilepsy, 243
 - foetal scans, 361–362
 - logit link function, 117
- oedema status, 275, 278
- offset, Poisson distribution, 110
- one-parameter distributions, 109–111
- order effects, 272
- ordered categorical data: *see under* ordinal
 - logistic regression
- ordinal logistic regression, 153–158
 - binary data, 301
 - categorical data, 305, 339, 341, 343
 - see also* mixed ordinary logistic regression
- ordinary least squares, 50, 83
- outliers, 79–80
 - GLMM model checking, 136–137
 - meta-analysis, 203–204
 - multi-centre analysis, 83, 86
 - Pearson residual plots, 239
 - polynomial random coefficients model, 228, 249, 255
 - random coefficients model, 249
 - random effects model, 184
 - repeated measures analysis, 231–238
 - SOLUTION option, 412
- ovarian cancer trial, 246
- over-dispersion, 134
- overfitting, 223–224
- overinterpretation of data, 260
- overparameterisation, 36
 - p-values, Bayesian, 58, 78–79
- parallel group design, 276, 307–308, 356
- parameter estimation, Bayesian, 60
- parameterisation, 160, 167
- Parkinsonism drug trial, 287–289
- PARMS statement, 420
- partitioning
 - categorical data, 202
 - extended binary form, 154
 - proportional odds assumption, 167
- patient: *see* subject
- PDIF option, 413, 427
- Pearson residuals, 147, 239
- period effect: *see also* time effect, 275
- pharmaceutical industry
 - empirical variance, 228
 - model choice, 295
- physiological response, 216
- plaque score, 277
- PM option, 408, 410
- Poisson data
 - covariance pattern model fitting, SAS, 428
 - dispersion parameter, 133
 - shrinkage, 131–132
- Poisson distribution
 - general exponential form, 118
 - model checking, 240
 - offset, 110
 - variance matrix, 114
- Poisson regression: *see* log linear models
- polynomial model building, 252–255
- pooled comparison, 274
- population bioequivalence, 378, 382, 383
- population averaged method: *see* marginal
 - quasi-likelihood
- post-operative complications, 371
- posterior density, 58–59
 - conditional, 420
 - determination, 58–59
 - rejection sampling, 68
- posterior distribution, 57, 59
 - evaluation, 66–70
 - marginal, 59
 - SAS, 102
 - simulated, 67, 68
- power: *see* sample size estimation
- pre-eclampsia, 204–213
- pre-eclampsia trial
 - see also* odds ratio; significance testing
- pre-treatment: *see under* baseline covariate
- predicted values, 428
- Prescott's test, 301, 304
- prior distribution, 57
 - conjugate, 65
 - flat, 61, 65, 420
 - informative, 75
 - non-informative, 57, 64
 - 'cold feet' analysis, 137, 143
 - prior similarity, 61
 - specification, 61–66
- PRIOR statement, 100, 420–421
 - default, 68
- proper, 65
- properties, 65–66

- probability
 - cumulative, 154, 155
 - multinomial, 163
 - see also* p-values
- probability intervals, 59
- probit function, 113
- PROC GENMOD, 146, 428–430
- PROC GLIMMIX, 133, 144, 170, 244, 295, 423
- PROC MIXED, 403–423
 - base density, 68
 - default fitting, 54
 - empirical variance, 76
 - negative variance, 71
 - statement options: *see also* specific statement, 425
 - syntax, 403
 - variance parameter fixing, 75
- proportional odds assumption, 167
- protocol checking, multi-centre trial, 184
- pseudo-likelihood, 125–127
 - 'cold feet' analysis, 141
 - GLIMMIX macro, 423
- pseudo variable, 116, 125–126

- quadratic function, 52
- quadratic random coefficients model, 257–260
- qualitative variables: *see* categorical effects
- quasi-likelihood, 123–124
 - categorical, 168
 - GLMM, 123
 - maximisation, 124–128

- R** matrix, 39
 - banded covariance, 223
 - compound symmetry structure, 222
 - covariance pattern model, 43–44
 - general structure, 222
 - GLMM, 121
 - mixed ordinal logistic regression, 159–161
 - random coefficients model, 41
 - random effects model, 39
 - repeated measures, 219, 222
 - REPEATED statement, 418–419
 - submatrices, 43
 - uncorrelated, 222
- radiologist reliability, 361–362

- random coefficients model, 22, 249
 - covariance pattern model comparison, 325
 - covariance structure, 41–43
 - cubic, 260
 - error stratum, 32
 - examples, 249–267
 - fitting by GEE, 126
 - GLMM V matrix, 121
 - likelihood function, 122
 - linear, 246
 - model fitting, 246
 - repeated measures (HIV), 250–252
 - model checking, 255
 - non-linear, 252
 - polynomial (childhood cancer), 252, 263
 - quadratic, 257–260
 - random effects, 21
 - RANDOM statement, 261, 412
 - repeated measures, 20–21, 245
 - repeated measures within visits, 323–325
 - shrinkage of estimates, 248
 - significance testing, 76–79, 248
 - systolic blood pressure trial, 323–329
 - see also* count data; covariance pattern model; event history analysis; random coefficients model
- random effects coefficient, 36, 50–52
- random effects estimation, 11–12
- random effects model, 22, 161–162
 - assumptions, 6
 - balance, 29–30
 - 'cold feet' analysis, 141
 - complete block designs, 279–280
 - compound symmetry, 220
 - covariance pattern comparison, 291–296
 - covariance structure, 38–40
 - cross-over trial, 137, 308–310
 - fitting by GEE, 126
 - fitting software, 167, 401–403
 - fixed models comparison, 6–8
 - GLMM, 120, 122
 - hierarchical, 18
 - likelihood, 122
 - model checking, 79–80
 - multi-centre trial, 184, 195, 204
 - negative variance, 70, 70
 - pre-eclampsia trial, 204–213
- R** matrix, 161
- random coefficient models, 21
- reparameterisation, 127, 161–162

- random effects model, (*continued*)
 - significance testing, 76–79
 - standard error bias, 142
 - uniform effects, 129–130, 134
 - V** matrix, 121
 - see also* reparameterisation
- RANDOM statement, 261, 318–320, 410–413
- random vs. fixed effects modelling, 7
- randomisation, cross-over trial, 272
- ranking, 304, 368–370
- reciprocal distribution, 61
- recovery of information
 - binary data cross-over, 299–303
 - cross-over, 274, 276
 - incomplete block, 284
 - Koch's design, 285
 - matched sets, 339
 - two-subject period cross-over, 286
- reference category, 149
- rejection sampling: *see under* Monte Carlo methods
- relative rate, 131, 239
- relative risk, 131
 - see also* log link function
- REML (residual maximum likelihood)
 - DBP analysis model, 84
 - definition, 46
 - empirical Bayes, 68
 - fixed effects estimation, 49
 - historical, 25
 - log likelihood, PROC MIXED, 403
 - model fitting, 46
 - random effects prediction, 50–52
 - standard error, 87
- reparameterisation
 - case control, 343
 - GLMM, 127, 161
 - mixed categorical, 161–162
 - random effects models as covariance pattern model, 127, 160–161
- repeated measures, 215–218
 - analyses by time point, 216
 - banded covariance, 223
 - containment stratum, 31
 - covariance pattern model, 218–228
 - count data, 237
 - normal data, 228–237
 - different covariances, 222
 - different variances, 221
 - error stratum, 31
 - event history, 372
 - fixed effects model, 216–217, 225–226
 - hypertension trial, 18–21
 - linear, 245, 250–252
 - mixed model, 3, 217
 - model choice, 225–226, 249
 - non-comparative datasets, 248
 - polynomial, 252–254
 - sample size estimation, 269
 - see also* outliers
- repeated measures within visits, 311–329
 - covariance structure, 314
 - cross-over trial (SBP)
 - covariance pattern choice, 317–322, 325–329
 - random coefficients, 323–329
 - reps cross-over, 317–322, 325–329
 - defined, 311
 - multi-centre trial, 330–334
 - random coefficients model, 323–329
 - treatment-reps interaction, 311–312
- REPEATED statement, 318–320, 418–419, 429
- Replicate cross-over designs
 - bioequivalence studies with, 378–392
- residual, 4, 428
 - error strata, 30
 - full, 47
 - homogeneity, 80
 - normal distribution, 4
 - Pearson, 137
 - standardised, 80
 - see also* R matrix; residual plots
- residual maximum likelihood: *see* REML
- residual plots
 - covariance pattern model, 228
 - GLMM, 136
 - matched case–control, 341
 - normal data, 79–80, 89–91
 - polynomial random coefficients model, 239, 245
 - repeated measures, 231–238, 245
 - SAS code, 146
- residual variance, 4–6
- response profile, 216
- restricted IGLS, 48, 56
- restricted maximum likelihood: *see* REML
- robust methods, 80
- run-in period, 272, 291

- s, 402
- safety trials, 246
- sample size
 - model selection, 371
 - shrinkage, 368–371
 - small, 309
- sample size estimation
 - animal physiology trial, 356–361
 - categorical data, 270
 - multi-centre trial, 197–202
 - non-normal data, 201–202
 - precision of, 202
 - repeated measures, 269
- sampling cost
 - binary data, 201
 - normal data, 199
- SAS
 - empirical standard error, 333
 - GLIMMIX macro, 427
 - Lipsitz macro source, 401
 - ordinal logistic regression macro, 305
 - PROC GENMOD, 149, 428–430
 - PROC MIXED, 403–423
 - base density, 76
 - default fitting, 54
 - empirical variance, 76
 - negative variance, 76
 - statement options: *see also* specific statement, 425
 - residual plots, 146
 - syntax, 403
 - variance parameter fixing, 76
 - uniform reference category, 146
 - V** matrix, 410
- SATTERTH option, 407, 409
- Satterthwaite DF, 77–78
 - GLMM, 136
 - repeated measures data, 226
- Schwarz's information criterion, 225, 405
- sensitivity analysis, 359
- shrinkage, 12, 24
 - bias, 127, 131, 134
 - dispersion parameter as metric, 134
 - ESTIMATE statement, 416–417
 - GLMM, 131–132, 134
 - hierarchical multi-centre trial, 338
 - meta-analysis, 203–204
 - random coefficients estimates, 248
 - random effects, 51, 203, 204, 206
 - ranking, 368–370
 - raw data comparison, 368–370
 - small area mortality, 368, 368
 - surgeon performance, 371
 - treatment by centre, 189
- side effects, 80, 246
- significance testing, 76–79
 - Bayesian: *see* p-values
 - 'cold feet' analysis, 137, 141
 - GLM, 135
 - GLMM, 135–136
 - negative variance components, 196
 - random coefficients model, 248
 - repeated measures, 226
- small area estimates, 367–370
- small sample bias, 293, 309
 - shrunk estimates, 368
- social deprivation score, 340–342
- SOLUTION option, 152, 408, 411–412, 426
- sparse data, 135, 295
- sphericity, test of, 220
- S-plus, 402
- SPSS, 402
- standard error, 49, 73, 87, 129, 143, 227–228
 - Bayesian, 60, 85–87
 - carry-over, 280, 286, 288
 - compound symmetry structure, 295
 - covariance pattern models, 23, 293
 - cross-over, 308
 - different variances, 351, 352
 - empirical
 - 'cold feet' analysis, 173
 - model-based comparison, 231, 241
 - fixed effects, 49, 227–228
 - heart failure cross-over trial, 276
 - hypertension study, 85–87
 - increase by mixed model, 184
 - linear random coefficients model, 250
 - model-based, compound symmetry structure, 293
 - model-based/empirical
 - covariance pattern model (cross-over), 293, 319
 - epilepsy trial, 243
 - model choice, 10, 277, 295
 - multi-centre trial, 188–190, 203
 - random effects, 132
 - repeated measures fixed effects, 217
 - simple model, 5
 - treatment-centre interaction, 86, 87
 - treatment, fixed effects model, 185
- Stata, 403

- Statistica, 403
 statistics, explaining results, 24
 subject effects, 3
 SUBJECT option, **G** matrix blocking, 412
 subject-time effects, 21
 submatrices, **R** matrix, 43
 sudden infant death syndrome: *see* cot death study
 summary statistics, 311
 surgical audit, 2
 syntax
 see also specific procedure or option
- t* test, 5, 77, 304, 370
 Taylor series, 116, 125
 test for trend: *see* chi-squared test; *t*-test
 time effect
 covariance patterns, 221
 model choice, 254
 non-linear models, 247
 random coefficients model, 20–21, 248, 323–325
 virus antibodies, 19, 252–260
 visit time–response model, 323–324
 time interval, 223
 time slope, 20–21, 323
 Toeplitz covariance pattern model, 220, 229
 repeated measures, 314
 SAS, 419, 429
 toxicology experiments, 113
 treatment effect estimates, 184–185
 binary data cross-over trial, 299–303
 DBP study, 88
 fixed effects, 184–185
 local/global, multi-centre trial, 203
 multi-centre trial with repeated measures, 331, 334
 random effects model, 183, 189
 relative rate, 239
 separate analyses by time, 217
 variance, 274
 treatment-centre: *see* centre-treatment
 treatment-rep effects, 326
 treatment-time effect
 hypertension trial, 19–20
 linear random coefficients model, 248
 omitted, 225–226
 random coefficients models, 246
 repeated measures, 231
 weighting, 231
 see also time effect
- trial design
 cross-over trial, 307–308
 inclusion criteria, 206
 optimisation, 356–361
 sensitivity analysis, 359
 variance components, 355–361
 see also sample size estimation
 trial-treatment, pre-eclampsia study, 204–206
 Type III tests: *see* Wald statistic
 TYPE option, 261
- ulcerative colitis, 375
 ultrasound scans
 dog cardiology, 363–364
 foetal, 361–362
 under-dispersion, 134
 uniform distribution, non-informative prior, 61
 uniform effect categories, 139
 ‘cold feet’ analysis, 137
 GLMM, 129–130
 reparameterisation, 343
 uniform reference category, standard error, 139
 unordered categorical data, 166
- V** matrix, 36, 38, 426
 Bernoulli distribution, 114
 between-subject trial, 352
 binomial distribution, 114
 fitting methods, 120
 GLM, 113–114
 GLMM, 120
 Poisson distribution, 114
 random coefficients model, 42
 random effects model, 39
 repeated measures within visits, 312–317
 SAS, 405, 410
 standard error bias, 87
 time origin invariance, 43, 260
- V** option, 411
 variance
 canonical link function, 113
 different variances, 221, 351–354
 dispersion parameter, 114–115, 121
 empirical, 76, 133, 228
 empirical/model based (PROC GENMOD), 428–430

- general exponential form, 111–112
- negative, 344
- non-convergence, 247
- randomisation, cross-over trial, 273
- sample size estimation, 201–202, 267
- variance components, 7, 420
 - animal physiology trial, 355
 - ANOVA, 8
 - Bayesian, 84
 - bias, 143
 - DBP, 88
 - estimation, 60
 - negative, 70–74, 130, 138, 196
 - random coefficients, 254
 - negative:Bayesian, 73
 - number of centres, 196
- variance matrix: *see* V matrix
- variance parameters
 - accuracy, 74, 142
 - bias, 48
 - pseudo-likelihood, 126
 - shrinkage, 131–132
 - covariance, 54
 - defined, 45
 - GEE, 126
 - IGLS, 54–56
 - maximum likelihood methods, 52
 - significance testing, 78, 136
- Wald statistic
 - GLM(M), 135
 - PROC MIXED (Type III test), 406
 - t* test, 77
 - Williams modification, dispersion parameter, 115
- washout, 272
- WEIGHT statement, 421
- weighting, treatment-time effect, 231
- WINBUGS, 403
- WinNonMen, 402
- withdrawal: *see* dropout
- within-subject design
 - animal physiology, 357–359
 - correlation, 20
 - cross-over trial, 273
 - see also* cross-over trial
- within-visit observations, correlation matrix, 312
- X** matrix, 35–36
 - mixed ordinal logistic regression, 156
 - unordered categorical data, 165
- Z** matrix, 37–38
 - mixed ordinal logistic regression, 162
 - random coefficients, 41
 - unordered categorical data, 165

